Applies to insulin glulisine: parenteral injection.

Side effects include:

Hypoglycemia, systemic hypersensitivity, injection site reaction.

For Healthcare Professionals

Applies to insulin glulisine: injectable solution, subcutaneous solution.

General

The most common adverse reactions reported include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, and rash.^[Ref]

Metabolic

Common (1% to 10%): Hypoglycemia, hypoglycemic seizure

Frequency not reported: Weight gain^[Ref]

Hypersensitivity

Common (1% to 10%): Local hypersensitivity reactions (redness, swelling, and itching at injection site) Uncommon (0.1% to 1%): Systemic allergic reactions including urticaria, chest tightness, dyspnea, allergic dermatitis, and pruritus

Frequency not reported: Anaphylaxis^[Ref]

In clinical trials of ups to 12 months duration, potential systemic allergic reactions were reported in 4.3% (79 of 1833) patients receiving insulin glulisine compared with 3.8% (58 of 1524) patients receiving comparator short-acting insulins. Permanent discontinuation occurred in 1 patient receiving insulin glulisine.^[Ref]

Local

Among patients using continuous subcutaneous insulin infusion pumps, the rates of catheter occlusions and infusion site reactions were similar with insulin glulisine compared with insulin aspart.^[Ref]

Common (1% to 10%): Infusion site reactions

Very rare (less than 0.01%): Catheter occlusions^[Ref]

Cardiovascular

Common (1% to 10%): Peripheral edema, hypertension^[Ref]

Gastrointestinal

Common (1% to 10%): Diarrhea, pharyngitis, vomiting, nausea^[Ref]

Dermatologic

Rare (less than 0.1%): Lipodystrophy^[Ref]

Immunologic

Common (1% to 10%): Influenza^[Ref]

Respiratory

Common (1% to 10%): Nasopharyngitis, upper respiratory tract infection, sinusitis, bronchitis^[Ref]

Musculoskeletal

Common (1% to 10%): Arthralgia, back pain^[Ref]

Nervous system

Common (1% to 10%): Headache^[Ref]

Genitourinary

Common (1% to 10%): Urinary tract infection^[Ref]